SCHEMBL9944348

SCHEMBL9944348

COc1c(Cl)cc(C(=O)Nc2ccc(C=O)cc2)cc1OCC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
TAS1R2 Q8TE23 1/20 0.53
MAPT P10636 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
LMNA P02545 3/20 0.46
GAA P10253 1/20 0.46
ABCB1 P08183 1/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.43
GFER P55789 1/20 0.43
MCL1 Q07820 1/20 0.43
RAB9A P51151 1/20 0.42
PLAU P00749 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12825320 0.88 TAS1R3 (0.56) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944238 0.87 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL1459365 0.87 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944285 0.83 TAS1R3 (0.57) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944293 0.82 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944346 0.81 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944351 0.79 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944295 0.79 MAPT (0.54) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944278 0.79 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2
SCHEMBL9944305 0.78 MAPT (0.57) TAS1R3TAS1R1TAS1R2MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.